Evgen Pharma was founded in 20007 and is based in Liverpool. It is a clinical stage drug development business focused on the treatment of cancer and neurological conditions. Its core technology is Sulforadex®, a patented, synthetic and stabilised version of a plant derived compound, sulforaphane. Sulforaphane is an established anti-cancer agent whose clinical and commercial development has, to date, been precluded by the instability of the molecule. The Group utilises its Sulforadex® technology to develop products that exploit the therapeutic properties of sulforaphane. The Group’s first development product, SFX-01, has completed Phase I trials and has been demonstrated to be safe and well tolerated.